Lavipharm S.A. Share Price

LAVI

GRS246003008

Pharmaceuticals

Market Closed - Athens S.E. 07:44:19 16/10/2026 pm IST			5-day change	1st Jan Change
1.508 ^EUR	-0.13%		-0.13%	+55.46%

17/09	Lavipharm S.A. Reports Earnings Results for the Half Year Ended June 30, 2026	CI
25/06	Lavipharm S.A. announces Annual dividend, payable on July 24, 2026	CI

Lavipharm SA is a Greece-based pharmaceutical and healthcare company engaged in the research and development of drug delivery solutions and the commercialisation of pharmaceutical, over-the-counter (OTC) and related healthcare products. It is active in the provision of prescription medicines, OTC products and food supplements, supported by integrated activities across research and development, manufacturing and commercial operations. It maintains a portfolio focused primarily on therapeutic areas including cardiology, central nervous system disorders, urology, oncology and chronic pain, supplying solutions designed for healthcare professionals and patients. The Company operates in both domestic and international markets and combines product development capabilities with market access and distribution activities, while acting as the parent entity of the Lavipharm Group through which its broader operations are conducted.

Employees

306

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
16/26/16	€1.508	-0.13%	6,052
15/26/15	€1.510	+0.13%	31,861
14/26/14	€1.508	+0.13%	42,915
13/26/13	€1.506	-0.92%	46,701
12/26/12	€1.520	+0.66%	39,045

Delayed Quote Athens S.E.

More quotes

Stock Market
Stocks
LAVI Stock

The best tools reserved for subscribers to boost the performance of your investments!

Market Cap	26Cr 29Cr 24Cr 22Cr 41Cr 2.75TCr 42Cr 286.92Cr 112.5Cr 1.43TCr 108.73Cr 106.42Cr 4.57TCr	P/E 2024	14.9x	P/E 2025	27.9x
Enterprise Value	28Cr 32Cr 26Cr 24Cr 45Cr 3.03TCr 46Cr 316.64Cr 124.15Cr 1.58TCr 119.99Cr 117.44Cr 5.05TCr	EV / Sales 2024	3.07x	EV / Sales 2025	3.04x
Free-Float	38.91%	Yield 2024	2.52%	Yield 2025	2.06%

17/09	Lavipharm S.A. Reports Earnings Results for the Half Year Ended June 30, 2026	CI
25/06	Lavipharm S.A. announces Annual dividend, payable on July 24, 2026	CI
28/05	Lavipharm Q1 earnings before tax from continuing operations EUR1.41 million, up 28.6% Y/Y	RE
28/05	Lavipharm S.A. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
09/04	Lavipharm to acquire Durogesic pain patch rights from Janssen for $12.0 million	RE
19/03	Lavipharm SA FY 2025 earnings after tax EUR 6.0 million versus EUR 9.0 million year ago	RE
19/03	Lavipharm S.A. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
17/11	Lavipharm 9-month net profit down to EUR 3.5 million	RE
18/25/18	Lavipharm H1 adjusted EBITDA at EUR 7.7 million, up 29.4% Y/Y	RE
18/25/18	Lavipharm S.A. Reports Earnings Results for the Half Year Ended June 30, 2025	CI
03/25/03	Lavipharm S.A. announces Annual dividend, payable on July 24, 2025	CI
15/25/15	Lavipharm Q1 Net Profit At EUR 1.6 Million, Up 46.8% YoY	RE
14/25/14	Lavipharm And Tikun Olam Europe Launch Joint Telemedicine Company	RE

01/10	Lavipharm S A : Announcement	PU
03/09	Lavipharm S A : Announcement Appointment of Chief Manufacturing & Operations Officer	PU
11/06	Lavipharm S A : Announcement Appointment of Chief Quality Officer	PU
22/05	Lavipharm S A : IMPORTANT CORPORATE EVENTS	PU
07/11	Lavipharm S A : OTHER ANNOUNCEMENTS	PU

1 day	-0.13%
1 week	-0.13%
Current month	-4.19%
1 month	-6.34%
3 months	+4.72%
6 months	+6.20%
Current year	+55.46%

1 week	1.48	1.56
1 month	1.46	1.61
Current year	0.94	1.74
1 year	0.78	1.74
3 years	0.58	1.74
5 years	0.35	2.22
10 years	0.21	2.22

Lavipharm S.A. Share Price

Stocks

LAVI

GRS246003008

Pharmaceuticals

Valuation: Lavipharm S.A.

Chart: Lavipharm S.A.

Latest news: Lavipharm S.A.

Press Releases: Lavipharm S.A.

Quotes and Performance

Price Extremes

Managers and Directors: Lavipharm S.A.

Latest insider transactions

Generic Pharmaceuticals

Financials

Company Profile

Quotes

Manager	Title	Age	Since
Vassilis Baloumis DFI	Director of Finance/CFO	-	01/12/2021
Ligia Panaitescu CTO	Chief Tech/Sci/R&D Officer	-	-
Eleana Nikolopoulou CMP	Compliance Officer	-	-

Director	Title	Age	Since
Venetsiana-Loukia Lavida BRD	Director/Board Member	-	-
Christos Panagiotis Diamantopoulos BRD	Director/Board Member	76	-
Minas G. Tanes CHM	Chairman	86	01/01/2021

Date	Insider	Type	Main position	Quantity	% Market Cap.
12/02/25	Vassilis Baloumis	Buy	Chief Financial Officer	20,000	0.0119%
27/05/23	Thomas Tseronis	Sell		35,434	0.0189%
28/03/23	Vassilis Baloumis	Buy	Chief Financial Officer	23,455	0.0125%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
LAVIPHARM S.A.	-0.13%	-0.13%	+88.97%	+153.02%	29Cr
ELI LILLY AND COMPANY	+0.43%	+6.59%	+56.57%	+106.64%	1,12000Cr
JOHNSON & JOHNSON	+0.90%	-2.25%	+32.26%	+63.73%	62TCr
ABBVIE INC.	+0.71%	+3.24%	+24.33%	+91.33%	50TCr
ROCHE HOLDING AG	-0.13%	+5.98%	+33.66%	+50.18%	37TCr
MERCK & CO., INC.	+0.52%	+0.24%	+72.13%	+40.11%	36TCr
NOVARTIS AG	-0.95%	+4.70%	+19.65%	+42.71%	29TCr
ASTRAZENECA PLC	-1.98%	+3.73%	-0.89%	+10.43%	26TCr
AMGEN INC.	-0.35%	+4.25%	+44.74%	+52.06%	23TCr
GILEAD SCIENCES, INC.	-0.75%	+3.32%	+27.18%	+94.07%	19TCr
Average	-0.17%	+3.24%	+39.86%	+70.43%	39.41TCr
Weighted average by Cap.	+0.13%	+3.83%	+39.34%	+71.83%

	2024	2025
Net sales	5.29Cr 5.96Cr 4.91Cr 4.46Cr 8.43Cr 565.3Cr 8.56Cr 59Cr 23Cr 295Cr 22Cr 22Cr 940.41Cr	6.26Cr 7.04Cr 5.8Cr 5.28Cr 9.96Cr 668.21Cr 10Cr 70Cr 27Cr 348.7Cr 26Cr 26Cr 1.11TCr
Net income	89.82L 1.01Cr 83.25L 75.74L 1.43Cr 96Cr 1.45Cr 10Cr 3.92Cr 50Cr 3.79Cr 3.71Cr 159.53Cr	59.86L 67.34L 55.48L 50.48L 95.26L 64Cr 96.78L 6.67Cr 2.61Cr 33Cr 2.53Cr 2.47Cr 106.32Cr
Net Debt	2.83Cr 3.19Cr 2.63Cr 2.39Cr 4.51Cr 302.53Cr 4.58Cr 32Cr 12Cr 157.87Cr 12Cr 12Cr 503.28Cr	2.67Cr 3Cr 2.47Cr 2.25Cr 4.24Cr 284.79Cr 4.31Cr 30Cr 12Cr 148.61Cr 11Cr 11Cr 473.76Cr